Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 16/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 7/20 | 1.00 |
| ▸ | CDK2 | P24941 | 7/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 4/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.88 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.88 |
| ▸ | CLK2 | P49760 | 1/20 | 0.88 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.88 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.88 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.88 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.88 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.81 |
| ▸ | NPC1 | O15118 | 1/20 | 0.81 |
| ▸ | MAPT | P10636 | 1/20 | 0.81 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.72 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.72 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.72 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bohemine SCHEMBL29572816 | 1.00 | CDK1 (1.00) | CDK1CCNB1CDK2CCNB2CCNB3 | |
| SCHEMBL7112489 | 0.97 | CDK1 (0.94) | CDK1CCNB1CDK2CCNB2CCNB3 | |
| SCHEMBL7113555 | 0.96 | CDK1 (0.92) | CDK1CCNB1CDK2CCNB2CCNB3 | |
| SCHEMBL1216905 | 0.94 | CDK1 (1.00) | CDK1CCNB1CDK2CCNB2CCNB3 | |
| SCHEMBL24669662 | 0.90 | TDP1 (0.81) | CDK1CCNB1CDK2CCNB2CCNB3 | |
| SCHEMBL31069517 | 0.88 | TDP1 (0.87) | CDK1CCNB1CDK2CCNB2CCNB3 | |
| SCHEMBL2098182 | 0.87 | CDK2 (0.88) | CDK1CCNB1CDK2CCNB2CCNB3 | |
| SCHEMBL24668597 | 0.87 | TDP1 (0.85) | CDK1CCNB1CDK2CCNB2CCNB3 | |
| SCHEMBL2169283 | 0.87 | CDK2 (1.00) | CDK1CCNB1CDK2CCNB2CCNB3 | |
| SCHEMBL29783464 | 0.87 | CDK2 (1.00) | CDK1CCNB1CDK2CCNB2CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107904201-A | Differentiation of the human embryo stem cell to pancreatic endocrine pedigree | 詹森生物科技公司 | 2018-04-13 | — | — | CN | claimed |
| CN-102272291-B | Differentiation of human embryonic stem cells into the pancreatic endocrine lineage | 詹森生物科技公司 | 2018-01-16 | — | — | CN | claimed |
| EP-2346988-B1 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS TO THE PANCREATIC ENDOCRINE LINEAGE | JANSSEN BIOTECH INC (US) | 2017-05-31 | — | — | EP | claimed |
| US-20100273802-A1 | NEW PURINE DERIVATIVES HAVING, IN PARTICULAR, ANTI-PROLIFERATIVE PROPERTIES, AND THEIR BIOLOGICAL USES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIGUE (C.N.R.S.) | 2010-10-28 | — | — | US | claimed |
| US-20090030019-A1 | PURINE DERIVATIVES HAVING, IN PARTICULAR, ANTI-PROLIFERATIVE PROPERTIES, AND THEIR BIOLOGICAL USES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIGUE (C.N.R.S.) | 2009-01-29 | — | — | US | claimed |
| US-20030186999-A1 | Purine derivatives having, in particular, antiproliferative properties, and their biological uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIGUE (C.N.R.S.) | 2003-10-02 | — | — | US | claimed |
| EP-1308447-A1 | Purine derivatives having antiproliferative properties and biological uses thereof | Centre National de la Recherche Scientifique (C.N.R.S.) (FR) | 2003-05-07 | — | — | EP | claimed |
| US-20020049218-A1 | Purine derivatives having, in particular, antiproliferative properties, and their biological uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIGUE (C.N.R.S.) | 2002-04-25 | — | — | US | claimed |
| EP-0874847-A1 | NOVEL PURINE DERIVATIVES HAVING, IN PARTICULAR, ANTIPROLIFERATIVE PROPERTIES, AND BIOLOGICAL USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1998-11-04 | — | — | EP | claimed |
| WO-1997020842-A1 | NOVEL PURINE DERIVATIVES HAVING, IN PARTICULAR, ANTIPROLIFERATIVE PROPERTIES, AND BIOLOGICAL USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 1997-06-12 | — | — | WO | claimed |
| JP-11322610-A | — | — | None | — | — | JP | disclosed |
| EP-3025714-B9 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN MA INC (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3025714-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN MA INC (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | ARQULE, INC. | 2020-05-21 | — | — | US | disclosed |
| US-10421948-B2 | Methods for making pancreatic endocrine cells | JANSSEN BIOTECH, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20020065293-A1 | Cyclin dependent kinase inhibitor | INSTITUTE OF EXPERIMENTAL BOTANY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC | 2002-05-30 | — | — | US | disclosed |
| EP-1147108-A1 | SUBSTITUTED NITROGEN HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL USE THEREOF | Ustav Experimentalni Botaniky Akademie ved Ceské Republiky (CZ) | 2001-10-24 | — | — | EP | disclosed |
| US-6221873-B1 | CONTACTING SAID CELL WITH A COMPOUND 2-(HYDROXYALKYLAMINO)-6-BENZYLAMINO-9-ISOPROPYLPURINE; CDK4 CDK7 ENZYMES ARE INHIBITED IN SAID CELL. | INSTITUTE OF EXPERIMENTAL BOTANY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2001-04-24 | — | — | US | disclosed |
| WO-2000043394-A1 | SUBSTITUTED NITROGEN HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL USE THEREOF | ÚSTAV EXPERIMENTÁLNÍ BOTANIKY AV CR (CZ) | 2000-07-27 | — | — | WO | disclosed |
| JP-H11322610-A | CYCLIN-DEPENDENT KINASE INHIBITOR | CYCLACEL LTD | 1999-11-24 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273802-A1 | NEW PURINE DERIVATIVES HAVING, IN PARTICULAR, ANTI-PROLIFERATIVE PROPERTIES, AND THEIR BIOLOGICAL USES | PNP, TYMP, DPYD | CDK1 404/4885CCNB1 276/4885CDK2 226/4885 |
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | TP53, KRAS, VHL | CDK1 230/4885CCNB1 94/4885CDK2 170/4885 |
| US-20030186999-A1 | Purine derivatives having, in particular, antiproliferative properties, and their biological uses | PNP, TYMP, NUDT1 | CDK1 501/4885CCNB1 340/4885CDK2 359/4885 |
| US-20020049218-A1 | Purine derivatives having, in particular, antiproliferative properties, and their biological uses | PNP, TYMP, NUDT1 | CDK1 501/4885CCNB1 340/4885CDK2 359/4885 |
| US-20090030019-A1 | PURINE DERIVATIVES HAVING, IN PARTICULAR, ANTI-PROLIFERATIVE PROPERTIES, AND THEIR BIOLOGICAL USES | PNP, TYMP, NUDT1 | CDK1 516/4885CCNB1 327/4885CDK2 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.